Agios market cap by end of 2024? | Categorical | | | 7 months ago | |
FDA approval for Mitapivat by end of 2024? | Binary | | | 7 months ago | |
Agios stock price up by 30% by end of 2024? | Binary | | | 7 months ago | |
EMA approval for Mitapivat by end of 2024? | Binary | | | 7 months ago | |
Percentage increase in Agios stock price by end of 2024? | Categorical | | | 7 months ago | |
Number of new indications approved for Mitapivat by mid-2025? | Categorical | | | 7 months ago | |
Agios stock price reaches new all-time high by end of 2024? | Binary | | | 7 months ago | |
Mitapivat sales exceed expectations in Q4 2024? | Binary | | | 7 months ago | |
FDA approval for Mitapivat for Thalassemia by end of 2024? | Binary | | | 7 months ago | |
Next major acquisition or partnership for Agios by end of 2024? | Categorical | | | 7 months ago | |
Agios' market cap at year-end 2024? | Categorical | | | 7 months ago | |
Next major milestone for Mitapivat in thalassemia treatment by end of 2024? | Categorical | | | 7 months ago | |
FDA approval of Mitapivat for thalassemia by end of 2024? | Binary | | | 7 months ago | |
Agios stock price increase by 20% by September 30, 2024? | Binary | | | 7 months ago | |
Agios announces new partnership or acquisition by end of 2024? | Binary | | | 7 months ago | |
Number of new treatments announced by Agios by end of 2024? | Categorical | | | 7 months ago | |
Agios revenue growth in Q4 2024? | Categorical | | | 7 months ago | |
Outcome of Agios' next Phase 3 trial by June 30, 2025? | Categorical | | | 7 months ago | |
Will Vorasidenib generate over $100 million in revenue by Q4 2024? | Binary | | | 5 months ago | |
Will Voranigo sales exceed $100 million in 2024? | Binary | | | 5 months ago | |
What will be the next major development in glioma treatments by August 7, 2025? | Categorical | | | 5 months ago | |
Will Vorasidenib be adopted by at least 50% of oncologists for low-grade glioma by end of 2024? | Binary | | | 5 months ago | |
Will Vorasidenib be approved in the EU by August 7, 2025? | Binary | | | 5 months ago | |
What will be the market share of Vorasidenib among IDH-mutant glioma treatments by end of 2024? | Categorical | | | 5 months ago | |
How many prescriptions for Vorasidenib will be issued by end of 2024? | Categorical | | | 5 months ago | |
Will Voranigo be included in the NCCN Guidelines for Grade 2 gliomas by the end of 2024? | Binary | | | 5 months ago | |
Will Voranigo receive EMA approval by June 30, 2025? | Binary | | | 5 months ago | |
What will be the percentage improvement in progression-free survival for Voranigo in the next INDIGO trial update? | Categorical | | | 5 months ago | |
Which major pharmaceutical company will announce a partnership or acquisition related to IDH mutation treatments by the end of 2024? | Categorical | | | 5 months ago | |
Which region will contribute the most to Voranigo sales in 2024? | Categorical | | | 5 months ago | |
